Injectable and oral contraceptives and risk of HIV acquisition in women: An analysis of data from the MDP301 trial

Human Reproduction

Volumn 29, Issue 8, 2014, Pages 1810-1817

  Crook, Angela M ^a   Ford, Deborah ^a   Gafos, Mitzy ^a,b   Hayes, Richard ^c   Kamali, Anatoli ^d   Kapiga, Saidi ^e   Nunn, Andrew ^a   Chisembele, Maureen ^f   Ramjee, Gita ^g   Rees, Helen ^h   McCormack, Sheena ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d MRC/UVRI Uganda Research Unit   (Uganda)

^e National Institute for Medical Research   (Tanzania)

^f UNIVERSITY TEACHING HOSPITAL   (Zambia)

^g HIV Prevention Research Unit   (South Africa)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Contraception; HIV; Sexual behaviour; Women

Indexed keywords

INJECTABLE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE; MICROBICIDE; NORETHISTERONE ENANTATE; ORAL CONTRACEPTIVE AGENT; PRO 2000; CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; FOLLOW UP; GENITAL SYSTEM; HAZARD RATIO; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SEROCONVERSION; CONTRACEPTIVE BEHAVIOR; HIV INFECTIONS; INCIDENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84904306928     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deu113     Document Type: Article

References (25)

1. Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. Aids 2013;27:105-113.
2. Cates W. Research on hormonal contraception and HIV. Lancet 2014; 383:303-304.
3. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008;168:656-664.
4. Gollub E, Stein Z. Living with uncertainty: acting in the best interests of women. AIDS Res Treat 2012;2012:524936.
5. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012;12:19-26.
6. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 2010;31:79-97.
7. Hernan MA, Lanoy E, Costagliola D, Robins JM. Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol 2006;98:237-242.
8. Jentsch U, Lunga P, Lacey C, Weber J, Cairns J, Pinheiro G, Joseph S, Stevens W, McCormack S. The implementation and appraisal of a novel confirmatory HIV-1 testing algorithm in the microbicides development programme 301 trial (MDP301). PLoS One 2012;7:e42322.
9. Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA, Mahoney CJ, Miller CJ, Claypool LE, Ho DD et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996;2:1084-1089.
10. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010;376:1329-1337.
11. McCoy SI, Zheng W, Montgomery ET, Blanchard K, van der Straten A, de Bruyn G, Padian NS. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. Aids 2013; 27:1001-1009.
12. Morrison CS, Nanda K. Hormonal contraception and HIV: an unanswered question. Lancet Infect Dis 2012;12:2-3.
13. Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, Byamugisha J, Padian N, Celentano DD, Salata RA. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. Aids 2010;24:1778-1781.
14. Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van deWijgert J, Gehret- Plagianos M, Patel S, Ahmed K, Ramjee G, Friedland B et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. Aids 2012;26:497-504.
15. Nunn A, McCormack S, Crook AM, Pool R, Rutterford C, Hayes R. Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention. Trials 2009;10:99.
16. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis 2013;13:797-808.
17. Polis CB,Westreich D, Balkus JE, Heffron R. Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches. Aids 2013;27(Suppl 1):S35-S43.
18. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M Lees S, Stadler J, Crook A, Nunn A et al. A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme. PLoS One 2010a;5:e11600.
19. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, Lees S, Stadler J, Nunn A, Crook A et al. Assessing the accuracy of adherence and sexual behaviour data in the MDP301 vaginal microbicides trial using a mixed methods and triangulation model. PLoS One 2010b;5:e11632.
20. Ralph LJ,McCoy SI, Hallett T, Padian N. Next steps for research on hormonal contraception and HIV. Lancet 2013;382:1467-1469.
21. Ralph L, McCoy S, Hallett T, Padian N. Research on hormonal contraception and HIV-authors' reply. Lancet 2014;383:305-306.
22. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560.
23. Tomasicchio M, Avenant C, Du Toit A, Ray RM, Hapgood JP. The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor. PLoS One 2013;8:e62895.
24. Trunova N, Tsai L, Tung S, Schneider E, Harouse J, Gettie A, Simon V, Blanchard J, Cheng-Mayer C. Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology 2006;352:169-177.
25. WHO. Hormonal Contraception and HIV Technical Statement. World Health Organisation, 2012.